 In an initial six-month phase II trial, results have shown significant improvement over placebo at 12 months.Latrepirdine showed promising results in a phase III-equivalent, double-blind trial in Russia with mild–moderate stage patients.In April 2009, Pfizer and Medivation initiated a phase III trial (CONCERT study) aiming for FDA approval.